ArticleKidney international reports2017
Efficacy and Safety of Sparsentan Compared With Irbesartan in Patients With Primary Focal Segmental Glomerulosclerosis: Randomized, Controlled Trial Design (DUET).
Radko Komers et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
27 papers cite it
this paperpooled ittrialcites it